Linical Co., Ltd. (2183.T)
JPY 330.0
(0.92%)
JPY 330.0
(0.92%)
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2023 | 10.3 Billion JPY | 4.26% |
| 2022 | 9.88 Billion JPY | 7.74% |
| 2021 | 9.17 Billion JPY | -4.13% |
| 2020 | 9.56 Billion JPY | 7.24% |
| 2019 | 8.92 Billion JPY | 11.41% |
| 2018 | 8 Billion JPY | 98.09% |
| 2017 | 4.04 Billion JPY | -3.83% |
| 2016 | 4.2 Billion JPY | 2.4% |
| 2015 | 4.1 Billion JPY | 14.62% |
| 2014 | 3.58 Billion JPY | 263.79% |
| 2013 | 984.59 Million JPY | -6.94% |
| 2012 | 1.05 Billion JPY | -1.4% |
| 2011 | 1.07 Billion JPY | 38.11% |
| 2010 | 776.97 Million JPY | 120.01% |
| 2009 | 353.14 Million JPY | 3.99% |
| 2008 | 339.59 Million JPY | 0.0% |
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2024 Q1 | 10.8 Billion JPY | 4.82% |
| 2023 Q2 | 10.23 Billion JPY | 2.63% |
| 2023 FY | 10.3 Billion JPY | 4.26% |
| 2023 Q4 | 10.3 Billion JPY | 4.53% |
| 2023 Q3 | 9.85 Billion JPY | -3.72% |
| 2023 Q1 | 9.97 Billion JPY | 0.94% |
| 2022 Q1 | 9.64 Billion JPY | 5.19% |
| 2022 Q2 | 10.09 Billion JPY | 4.62% |
| 2022 Q3 | 9.84 Billion JPY | -2.51% |
| 2022 Q4 | 9.88 Billion JPY | 0.41% |
| 2022 FY | 9.88 Billion JPY | 7.74% |
| 2021 Q2 | 8.72 Billion JPY | -4.17% |
| 2021 Q1 | 9.1 Billion JPY | -4.79% |
| 2021 Q3 | 9.27 Billion JPY | 6.29% |
| 2021 Q4 | 9.17 Billion JPY | -1.14% |
| 2021 FY | 9.17 Billion JPY | -4.13% |
| 2020 FY | 9.56 Billion JPY | 7.24% |
| 2020 Q2 | 8.84 Billion JPY | -7.95% |
| 2020 Q1 | 9.61 Billion JPY | 7.74% |
| 2020 Q3 | 9.17 Billion JPY | 3.69% |
| 2020 Q4 | 9.56 Billion JPY | 4.28% |
| 2019 FY | 8.92 Billion JPY | 11.41% |
| 2019 Q4 | 8.92 Billion JPY | 1.93% |
| 2019 Q1 | 8.75 Billion JPY | 9.32% |
| 2019 Q3 | 8.75 Billion JPY | 2.47% |
| 2019 Q2 | 8.54 Billion JPY | -2.43% |
| 2018 Q1 | 8.76 Billion JPY | 116.77% |
| 2018 FY | 8 Billion JPY | 98.09% |
| 2018 Q4 | 8 Billion JPY | -2.12% |
| 2018 Q3 | 8.18 Billion JPY | -7.62% |
| 2018 Q2 | 8.85 Billion JPY | 1.07% |
| 2017 Q4 | 4.04 Billion JPY | -5.54% |
| 2017 Q1 | 4.25 Billion JPY | 1.25% |
| 2017 FY | 4.04 Billion JPY | -3.83% |
| 2017 Q2 | 4 Billion JPY | -5.96% |
| 2017 Q3 | 4.27 Billion JPY | 6.92% |
| 2016 Q4 | 4.2 Billion JPY | 9.02% |
| 2016 Q1 | 3.95 Billion JPY | -3.65% |
| 2016 FY | 4.2 Billion JPY | 2.4% |
| 2016 Q2 | 3.67 Billion JPY | -7.13% |
| 2016 Q3 | 3.85 Billion JPY | 4.97% |
| 2015 Q2 | 4.37 Billion JPY | 2.96% |
| 2015 Q4 | 4.1 Billion JPY | -6.51% |
| 2015 Q1 | 4.24 Billion JPY | 18.57% |
| 2015 FY | 4.1 Billion JPY | 14.62% |
| 2015 Q3 | 4.39 Billion JPY | 0.43% |
| 2014 FY | 3.58 Billion JPY | 263.79% |
| 2014 Q1 | 1.1 Billion JPY | 12.52% |
| 2014 Q4 | 3.58 Billion JPY | 7.24% |
| 2014 Q3 | 3.33 Billion JPY | 219.15% |
| 2014 Q2 | 1.04 Billion JPY | -5.54% |
| 2013 Q3 | 947.58 Million JPY | 9.25% |
| 2013 Q4 | 984.59 Million JPY | 3.91% |
| 2013 FY | 984.59 Million JPY | -6.94% |
| 2013 Q1 | 1.05 Billion JPY | 0.07% |
| 2013 Q2 | 867.35 Million JPY | -18.07% |
| 2012 Q1 | 1.1 Billion JPY | 3.07% |
| 2012 Q2 | 962.18 Million JPY | -13.01% |
| 2012 Q3 | 986.85 Million JPY | 2.56% |
| 2012 Q4 | 1.05 Billion JPY | 7.21% |
| 2012 FY | 1.05 Billion JPY | -1.4% |
| 2011 Q1 | 842.85 Million JPY | 8.48% |
| 2011 FY | 1.07 Billion JPY | 38.11% |
| 2011 Q2 | 849.51 Million JPY | 0.79% |
| 2011 Q3 | 941.76 Million JPY | 10.86% |
| 2011 Q4 | 1.07 Billion JPY | 13.94% |
| 2010 Q3 | 820.67 Million JPY | 135.09% |
| 2010 Q4 | 776.97 Million JPY | -5.33% |
| 2010 FY | 776.97 Million JPY | 120.01% |
| 2010 Q2 | 349.09 Million JPY | 0.0% |
| 2009 Q1 | 447.06 Million JPY | 31.64% |
| 2009 FY | 353.14 Million JPY | 3.99% |
| 2009 Q4 | 353.14 Million JPY | 5.38% |
| 2009 Q3 | 335.11 Million JPY | -19.63% |
| 2009 Q2 | 416.95 Million JPY | -6.73% |
| 2008 Q4 | 339.59 Million JPY | 0.0% |
| 2008 FY | 339.59 Million JPY | 0.0% |
| Name | Total Liabilities | Total Liabilities Difference |
|---|---|---|
| KOHJIN BIO CO LTD | 3.24 Billion JPY | -217.373% |
| PRISM BioLab Co.,LTD | 63.41 Million JPY | -16150.955% |
| GNI Group Ltd. | 26.34 Billion JPY | 60.88% |
| Trans Genic Inc. | 3.81 Billion JPY | -170.29% |
| MEDINET Co., Ltd. | 590.2 Million JPY | -1645.988% |
| Soiken Holdings Inc. | 697.02 Million JPY | -1378.415% |
| Cytori Cell Research Institute, Inc. | 3.02 Billion JPY | -241.137% |
| AnGes, Inc. | 2.78 Billion JPY | -269.435% |
| OncoTherapy Science, Inc. | 513.6 Million JPY | -1906.377% |
| Nxera Pharma Co., Ltd. | 90.38 Billion JPY | 88.599% |
| Immuno-Biological Laboratories Co., Ltd. | 353.27 Million JPY | -2816.994% |
| NanoCarrier Co., Ltd. | 1.64 Billion JPY | -524.581% |
| Carna Biosciences, Inc. | 472.35 Million JPY | -2081.599% |
| CanBas Co., Ltd. | 91.98 Million JPY | -11102.432% |
| D. Western Therapeutics Institute, Inc. | 1.09 Billion JPY | -842.286% |
| RaQualia Pharma Inc. | 809.83 Million JPY | -1172.476% |
| Chiome Bioscience Inc. | 593.73 Million JPY | -1635.616% |
| Kidswell Bio Corporation | 4.25 Billion JPY | -142.236% |
| PeptiDream Inc. | 29.11 Billion JPY | 64.605% |
| Oncolys BioPharma Inc. | 566.5 Million JPY | -1719.046% |
| Ribomic Inc. | 155.8 Million JPY | -6513.798% |
| SanBio Company Limited | 2.25 Billion JPY | -357.002% |
| Healios K.K. | 11.28 Billion JPY | 8.693% |
| BrightPath Biotherapeutics Co., Ltd. | 251.26 Million JPY | -4001.14% |
| Kubota Pharmaceutical Holdings Co., Ltd. | 369 Million JPY | -2692.654% |
| Delta-Fly Pharma, Inc. | 241.49 Million JPY | -4167.089% |
| StemRIM | 187 Million JPY | -5410.638% |
| CellSource Co., Ltd. | 677.73 Million JPY | -1420.481% |
| FunPep Company Limited | 189.32 Million JPY | -5342.993% |
| Kringle Pharma, Inc. | 596.95 Million JPY | -1626.243% |
| Stella Pharma Corporation | 1.44 Billion JPY | -613.828% |
| TMS Co., Ltd. | 97.68 Million JPY | -10448.673% |
| Noile-Immune Biotech Inc. | 91.49 Million JPY | -11162.917% |
| Cuorips Inc. | 200.96 Million JPY | -5027.807% |
| K Pharma,Inc. | 209.13 Million JPY | -4827.412% |
| Takara Bio Inc. | 11.42 Billion JPY | 9.765% |
| ReproCELL Incorporated | 741.03 Million JPY | -1290.614% |
| PhoenixBio Co., Ltd. | 917.71 Million JPY | -1022.888% |
| StemCell Institute Inc. | 3.85 Billion JPY | -167.627% |
| Japan Tissue Engineering Co., Ltd. | 908.43 Million JPY | -1034.362% |
| CellSeed Inc. | 301.04 Million JPY | -3323.018% |